Search Videos and More
Neurological Injury Paradigm Shifts in CHD Patients
While surgical survival for complex congenital heart disease (CHD) now exceeds 90%, over half of these children still develop significant neurological dysfunction.More than a White Matter Injury: Vulnerability of the Preterm Brain and Periventricular Leukomalacia (PVL)
Neonatologists have remarkably improved survival rates for low birth weight infants to approximately 90%Fetal Anomalies & Perinatal Mental Health Implications for Practice
Strengths-based, trauma-informed care is key to the clinical approach our team at Phoenix Children’s uses for the unique aspects of care for expectant parents and infants.Super Resolution Fetal MRI
Super Resolution Fetal MRIs and their benefits including: enhanced visualization of fetal anatomy, potential for 3D and 4D reconstructions, improved diagnostic accuracy in complex congenital anomalies and highlighted the ongoing advancements and clinical impact of these techniques.Cardiac Evaluation and Potential for Prenatal through Postnatal Therapy
Dr. Lindblade led a discussion related to high risk fetal conditions (eg, sacrococcygeal teratoma, vein of Galen malformation, placental chorioangioma, etc.) and their cardiovascular implications.Patient and Family Perspective of Care – Assessing the Impact of Our Care
Dr. Deborah Tom moderated a panel discussion among parents of infants with BPD to explore how providers can better assess the needs of individual families and work within care teams to improve care delivery.Neuro-Sedative Use in the Inpatient Setting
Pharmacist Rhonda Kurz spoke on the variability in use of medications for BPD and variability of individual responses to medications.Emerging Therapies for Prevention and Treatment of BPD
Dr. Vlad Kalinichenko considered the use of novel pharmacologic treatments that may prevent BPD and/or more effectively treat the manifestations of BPD.Challenges of Pharmacologic Management of BPD and Research Highlights Relating to Diuretic Usage
Dr. Nicolas Bamat, assistant professor of Pediatrics in the Division of Neonatology & Center for Clinical Effectiveness at Children’s Hospital of Philadelphia, was the keynote speaker, exploring the evolution of pharmacologic management of BPD, and explaining how to apply the evidence for medication use to support local care guidelines and practiceSystemic Corticosteroids – Timing is Everything
Dr. Amy Brown presented on how the timing of use of systemic corticosteroids may prevent BPD and/or more effectively treat the manifestations of BPD.Therapies for BPD-Associated Pulmonary Hypertension – What Do We Know Now?
Dr. Kevin Engelhardt presented on therapy options for BPD-associated pulmonary hypertension.Inhaled Respiratory Medications - “Helpful, Harmful, or Just a Burden?”
Dr. Rajeev Bhatia assessed the risks and benefits of commonly used medications for infants with BPD, as well as at the individual level for the specific patient.